Dicot (DICOT) Q2 2026 earnings summary

Executive summary

• Completed a capital raise of SEK 231 million, strengthening financial position for phase 2b study of LIB-01 targeting erectile dysfunction.

• FDA clearance received to initiate Part I of phase 2b study in the US; Clinical Trial Application submitted in EU.

• LIB-01 abstracts accepted for oral presentation at SMSNA annual conference, highlighting scientific interest.

• Manufacturing of LIB-01 tablets completed; preparations for clinical trial advanced.

Financial highlights

• Net sales were MSEK 0.0 for both Q2 and H1 2026, unchanged year-over-year.

• Result after financial items: MSEK -18.4 for Q2 2026 (vs. -24.3 Q2 2025); MSEK -33.2 for H1 2026 (vs. -47.2 H1 2025).

• Earnings per share: SEK -0.01 for Q2 2026 (unchanged YoY); SEK -0.02 for H1 2026 (vs. -0.03 H1 2025).

• Operating expenses for Q2 2026 were SEK 18.7 million, down from SEK 25.0 million in Q2 2025.

• Cash and cash equivalents at June 30, 2026: SEK 248.4 million (vs. SEK 105.8 million a year earlier).

Outlook and guidance

• Phase 2b study of LIB-01 to be initiated in H2 2026 in both US and Europe.

• Additional preclinical toxicology study accelerated to meet FDA requirements.

• Company aims to establish industrial partnerships for out-licensing ahead of phase 3.